Effect of Selumetinib versus Chemotherapy on Progression-Free Survival in Uveal Melanoma: A Randomized Clinical Trial

IMPORTANCE: Uveal melanoma is characterized by mutations in GNAQ and GNA11, resulting in MAPK pathway activation. OBJECTIVE: To assess the efficacy of selumetinib, a selective, non-ATP competitive inhibitor of MEK1 and MEK2, in uveal melanoma. DESIGN: Randomized open-label phase II clinical trial co...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JAMA
Päätekijät: Carvajal, Richard D., Sosman, Jeffrey A., Quevedo, Jorge Fernando, Milhem, Mohammed M., Joshua, Anthony Michael, Kudchadkar, Ragini R., Linette, Gerald P., Gajewski, Thomas F., Lutzky, Jose, Lawson, David H., Lao, Christopher D., Flynn, Patrick J., Albertini, Mark R., Sato, Takami, Lewis, Karl, Doyle, Austin, Ancell, Kristin, Panageas, Katherine S., Bluth, Mark, Hedvat, Cyrus, Erinjeri, Joseph, Ambrosini, Grazia, Marr, Brian, Abramson, David, Dickson, Mark Andrew, Wolchok, Jedd D., Chapman, Paul B., Schwartz, Gary K.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2014
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4249701/
https://ncbi.nlm.nih.gov/pubmed/24938562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2014.6096
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia